Efforts in minimizing risk of viral transmission through viral inactivation
- 1 January 2000
- journal article
- review article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 32 (7) , 475-484
- https://doi.org/10.3109/07853890009002023
Abstract
The viral safety of blood and blood products has improved substantially over the last decade on account of the development of new viral screening and virucidal procedures. For nearly 15 years, virally inactivated blood derivatives, prepared by using advanced virucidal procedures, have amassed an extraordinary safety record with respect to hepatitis B and C and HIV. This record of safety has spawned the development of newer virucidal procedures designed to eliminate nonenveloped viruses from blood derivatives and viruses and other pathogens from blood components, including cellular components. Ongoing tests that include clinical studies will demonstrate how close we are to achieving a blood supply that is free of viruses, bacteria, and parasites.Keywords
This publication has 57 references indexed in Scilit:
- Large-Scale Screening for Human Parvovirus B19 DNA by PCR: Application to the Quality Control of Plasma for FractionationVox Sanguinis, 2000
- Transfusion transmitted Yersinia enterocolitica infection in New ZealandAustralian and New Zealand Journal of Medicine, 1997
- Human Parvovirus B19 and Blood ProductsVox Sanguinis, 1997
- The Risk of Transfusion-Transmitted Viral InfectionsNew England Journal of Medicine, 1996
- Molecular Cloning and Disease Association of Hepatitis G Virus: A Transfusion-Transmissible AgentScience, 1996
- Removal and Inactivation of Hepatitis A Virus (HAV) during Processing of Factor VIII ConcentratesVox Sanguinis, 1994
- Inactivation of Viruses in Blood and Plasma ProductsTransfusion Medicine Reviews, 1993
- Reassessment of blood donor selection criteria for United States travelers to malarious areasTransfusion, 1991
- Persistent parvovirus B19 infections in humansMicrobial Pathogenesis, 1989
- VIRUCIDAL TREATMENT OF CLOTTING FACTOR CONCENTRATESThe Lancet, 1988